Press coverage about Medidata Solutions (NASDAQ:MDSO) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medidata Solutions earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.3854036417173 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern’s rankings:

Shares of Medidata Solutions (NASDAQ:MDSO) opened at 79.46 on Tuesday. The company has a 50-day moving average price of $74.79 and a 200 day moving average price of $71.67. Medidata Solutions has a 12-month low of $46.10 and a 12-month high of $85.92. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of 128.37 and a beta of 1.77.

Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.03. The firm had revenue of $137.41 million during the quarter, compared to the consensus estimate of $134.28 million. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The business’s revenue was up 19.9% compared to the same quarter last year. During the same period last year, the company earned $0.24 earnings per share. Equities research analysts expect that Medidata Solutions will post $1.29 earnings per share for the current fiscal year.

MDSO has been the topic of several research reports. Morgan Stanley set a $74.00 target price on Medidata Solutions and gave the stock a “buy” rating in a research report on Wednesday, June 14th. BidaskClub lowered Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target (up from $75.00) on shares of Medidata Solutions in a report on Friday, July 21st. Bank of America Corporation assumed coverage on Medidata Solutions in a research note on Tuesday, June 6th. They issued a “buy” rating and a $85.00 price target for the company. Finally, Piper Jaffray Companies increased their price objective on Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a report on Friday, July 7th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Medidata Solutions presently has an average rating of “Buy” and an average price target of $83.83.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/03/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-medidata-solutions-mdso-share-price.html.

In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.80% of the stock is currently owned by company insiders.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.